Extended hours options trading

Extended hours options trading allows trading of certain U.S. equity and ETF options outside regular market hours (typically 9:30 a.m.–4:00 p.m. ET). As of October 19–20, 2026, major exchanges expanded access significantly for select high-volume products.

tradestation.com

Recent Expansion (Launched October 19, 2026)Cboe Options Exchange (and similarly NYSE American Options) introduced:

• Pre-market (Global Trading Hours / Early session): 7:30 a.m.–9:25 a.m. ET (orders may queue from around 7:15 a.m.).
• Post-market (Curb / Late session): 4:00 p.m.–4:15 p.m. ET.

CHARTS

• stockcharts 
• finviz - change from open %

Here is the current list of underlying stock and ETF tickers whose options are eligible for extended-hours trading (as of the October 19–20, 2026 launch on Cboe Options Exchange and NYSE American Options).

ir.cboe.com

Eligible Symbols (29 total)Stocks (24):
AAPL, AMD, AMZN, AVGO, BABA, BAC, F, GOOG, GOOGL, HOOD, INTC, META, MRVL, MSFT, MU, NFLX, NOK, NVDA, ORCL, PFE, PLTR, SNDK, TSLA, TSM

ETFs (5):
GLD, IWM, QQQ, SPY, XLFSession Times (ET, Monday–Friday)

• Pre-market / Early / GTH session: 7:30 a.m. – 9:25 a.m.
• Post-market / Late / Curb session: 4:00 p.m. – 4:15 p.m.
  (Certain ETFs like SPY, QQQ, IWM, GLD, and XLF already trade until 4:15 p.m. as part of their regular session.)

by Avg Volume▼

 

Stocks/ETFs that traded to new 52-week highs/lows this session

New lows (131) outpacing new highs (42)

Stocks that traded to 52-week highs:

• Communication Services: TJGC
• Energy: DINO, MPC, UGP, VLO
• Financials: AEAQ, AIIA, ALOV, CYPH, INAC, IPEX, LFAC, OBA, PACH, SDHI, SOCA
• Health Care: ATRC, FRNM, HELP, HSCS, ILMN, NEO, NTRA, PGEN, STLN, TKNO
• Industrials: ATKR, CXW, DHT, ETS, HAFN, NAT, PXS, TH, TISI, TRMD
• Information Technology: DELL, FFIV, RBRK, SMTC, USDEW

Stocks that traded to 52-week lows:

• Communication Services: CABO, CXDO, GOGO, IHRT, LFTO, SEAT, TME, TMUS, TU
• Consumer Discretionary: ADNT, BBW, BROS, BYD, CCL, CSV, FLWS, FWRG, GIL, GPI, INSE, JMKE, KRUS, LEN, LOW, MBC, MBUU, MCD, MNSO, NCLH, NKE, PATK, PLBY, PZZA, RENT, THO, VVV, WINA, XPOF, ZUMZ
• Consumer Staples: BGS, CLX, FLO, NATR, PEP, RLX, SFD, STZ
• Energy: AEC, ARRY
• Financials: CCAP, ENHA, GBFH, JRVR, LAZ, LU, MBI, NHIC, PAX, SAMG, VEL
• Health Care: ARDX, EVMN, IONS, KARD, KLRA, KRMD, MAZE, MBOT, MDLN, MGX, OFIX, ORGO, PHAT, RNA, SPRY, UPB, WVE
• Industrials: ERII, FIP, KSCP, MRLN, MWA, PNR, REZI, RTO, SARO
• Information Technology: AIBZ, FIS, GRAB, KDK, VRRM
• Materials: AMRZ, BLDR, FUL, LPX, MLM, TGLS, TTAM
• Real Estate: ABR, ADC, AIV, BHR, BRSP, CIGI, CMTG, ESRT, FCPT, GLPI, HGV, NHI, OPEN, PMT, SEVN, SUI, TRTX, VICI
• Utilities: CMS, EXC, HE, KEP, NRG, PEG, SOMN

ETFs that traded to 52-week highs: THYP

ETFs that traded to 52-week lows: ABI, BKMI, FMB, HYTR, IBTI, SMST, VTIP, WABF

========Werewolf Therapeutics (HOWL) to merge with Ambros Therapeutics in all-stock deal alongside $150 million private placement

 

WALTHAM, Mass. and SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) and Ambros Therapeutics, Inc., today announced that they entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Ambros Therapeutics’ neridronate development program in Complex Regional Pain Syndrome Type 1 (“CRPS-1”, formerly known as Reflex Sympathetic Dystrophy). Upon completion of the merger, the combined company will operate as Ambros Therapeutics, headquartered in San Diego, California, and is expected to trade under the Nasdaq ticker symbol “AMBX”.

• Proposed merger to create a Nasdaq-listed, late-stage biotechnology company advancing neridronate, a potential first FDA-approved treatment for CRPS-1, a debilitating orphan disease with 65,000 newly diagnosed U.S. patients annually and no currently FDA-approved therapy
• Pivotal CRPS-RISE Phase 3 trial evaluating neridronate remains ongoing, with FDA Breakthrough Therapy, Fast Track and Orphan Drug designations received and alignment with FDA that a single successful pivotal trial could potentially support approval
• Neridronate has been administered to approximately 600,000 patients in Italy across approved indications including CRPS-1
• Concurrent oversubscribed private placement of $150 million from a syndicate of leading healthcare-dedicated investors expected to fund company operations through CRPS-RISE Phase 3 topline results and planned NDA submission, with cash runway into 1H 2029

===Moderna (MRNA): Phase 3 melanoma mRNA therapy success with Merck (MRK)

Moderna (MRNA +142%) and Merck (MRK +11.3%) announced this morning that the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its primary and key secondary endpoints in high-risk melanoma.

Merck and Moderna Phase 3 INTerpath-001 topline data show V940 plus Keytruda met primary and key secondary endpoints in melanoma

• Trial enrolled patients with completely resected Stage IIB-IV melanoma receiving adjuvant intismeran autogene (V940) plus KEYTRUDA
• Merck and Moderna plan to engage regulators on filing submissions for the V940 and KEYTRUDA combination regimen

• The combination is the first and only regimen to demonstrate statistically significant and clinically meaningful improvements in both recurrence-free survival and distant metastasis-free survival compared with KEYTRUDA alone in this setting.

• The readout also marks the first positive Phase 3 trial for an individualized neoantigen therapy and an mRNA-based cancer therapy, providing major validation for Moderna's mRNA platform beyond infectious disease and potentially opening a meaningful new opportunity in oncology. As a result, MRNA shares are surging on the results.

• The results are supporting broader enthusiasm around precision medicine, computational biology and personalized therapeutics, with the landmark Phase 3 readout providing an important clinical proof point for highly individualized treatment approaches.

• Precision medicine and next-generation biotech names trading higher include Tempus AI (TEM +22.2%), BioNTech (BNTX +20.4%), Ginkgo Bioworks (DNA +15.3%), Prime Medicine (PRME +13.4%), Recursion Pharmaceuticals (RXRX +9.6%).